ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH EVAN YU
Management of mCRPC using Sipuleucel-T

VIEW ALL mCRPC VIDEOS

ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH JACOB BERCHUCK & MARY-ELLEN TAPLIN
Genetic Risk in Prostate Cancer

VIEW ALL PROSTATE CANCER VIDEOS

ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH KARIM FIZAZI
ARAMIS Trial in Prostate Cancer: Impact of Darolutamide on Pain and Quality of Life

VIEW ALL nmCRPC VIDEOS

EAU 2019 ANNUAL MEETING

EAU 2019 ANNUAL MEETING

INTERVIEW WITH THOMAS POWLES
Immunotherapy in the Peri-Operative Setting for Bladder Cancer

VIEW ALL BLADDER CANCER VIDEOS

Videos
State-of-the-industry video lectures by leading urology experts
Featured Videos

#WCE2014 - Encouraging long-term oncological outcomes of radical prostatectomy for high-risk prostate cancer management - Interview

TAIPEI, TAIWAN (UroToday.com) - Introduction and Objectives: To report the longterm oncological outcome associated with radical prostatectomy (RP) in a consecutive cohort of patients with high-risk prostate cancer (PC) and to identify the variables associated with disease progression.

wceMethods: Between 1998 and 2006, a total of 239 patients underwent RP for high-risk PC. High-risk PC was defined as follows: prostate-specific antigen (PSA) level > 20 ng/mL, Gleason score 8– 10, and/or clinical stage T2c-T4 disease. Biochemical recurrence (BCR) was defined as a postoperative PSA value ≥ 0.20 ng/mL and a confirmatory rise, or a postoperative PSA ≥ 0.20 ng/mL while receiving salvage treatment. Kaplan-Meier and multivariate cox regression analysis were used to determine BCR, cancer specific survival (CSS) and the significant predictors of BCR.

Results: The median follow-up was 64 months. Organ-confined disease, seminal vesicle invasion and lymph node metastasis were reported in 46% (64% corresponded to pT3), 27% and 3%, respectively. The positive surgical margin rate was 29%. Overall, the predicted 5-year and 10-year BCR-free survival rates were 31% and 29%, respectively; and the predicted 5-year and 10-year CSS rates were 98% and 89%, respectively. After adjusting for other covariates, higher pathologic stage, positive nodes, positive surgical margins and Gleason 8–10 are significantly associated with BCR.

Conclusions: Our data support evidence that RP can result in encouraging long-term oncologic outcomes for the management of high- risk PC.

Source of Funding: None

 
Listen to an interview with Eric Barret, one of the authors of this study.

 

Presented by Eric Barret,1 Youness Ahallal,1 Rafael Sanchez-Salas,1 Fernando Secin,2 Laurent Mascle,1 Petr Macek,1 Luca Lunelli,1 Camilo Gieledman,1 Marc Galiano,1 Francois Rozet,1 and Xavier Cathelineau1 at the 32nd World Congress of Endourology & SWL - September 3 - 7, 2014 - Taipei, Taiwan

1Department of Urology, Institut Montsouris- Paris-Descartes University, Paris, France
2Department of Urology, San Lazaro Foundation and CEMIC, Buenos Aires, Argentina
 

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 4 Issue 1

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe